Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.

Historically, HER2-mutated lung cancer was treated with cytotoxic chemotherapy, unlike other oncogene-driven cancers that used targeted therapies upfront. Zongertinib's approval as a first-line oral TKI marks a significant philosophical shift, aligning its treatment strategy with the biomarker-driven care standard in lung oncology.

Even if randomized trials show zongertinib's efficacy is merely comparable to chemoimmunotherapy, its significantly milder safety profile—especially its lack of cardiac toxicity and manageable side effects—is expected to make it the preferred first-line choice. Patient quality of life and tolerability are becoming decisive factors in treatment selection.

Unlike the standard chemotherapy regimen TCHP, the newer drug T-DXd can cross the blood-brain barrier. This is a crucial advantage for high-risk HER2-positive breast cancer patients, as it offers the potential to prevent brain metastases, a common and devastating site of recurrence for this cancer subtype.

The B7H3-targeted antibody-drug conjugate (ADC) ifanatumab deruxtecan shows a high intracranial response rate in SCLC, numerically even better than its systemic response rate. This suggests excellent CNS penetration, offering a promising strategy for managing brain metastases, a common and difficult challenge in SCLC.

While TROP2-ADCs are currently approved for later-line lung cancer treatment, active clinical trials are already evaluating them as a potential replacement for traditional chemotherapy in the first-line setting. This represents a significant strategic ambition to shift the entire treatment paradigm for newly diagnosed patients with both non-small cell and small cell lung cancer.

The development of new KIT inhibitors like bezuclastinib is largely fueled by the need for alternatives to high-dose avapritinib in advanced SM. Concerns about cognitive effects and rare intracranial hemorrhage with avapritinib create an opportunity for agents with less blood-brain barrier penetration.

In notoriously hard-to-treat small cell lung cancer (SCLC), ADCs are emerging as a crucial next step. They hold promise for patients who progress after chemoimmunotherapy and newer targeted agents like tarlatamab, a setting where treatment options are currently scarce. ADCs could provide meaningful responses in this significant unmet need.

Unlike the intact blood-brain barrier, the blood-tumor barrier within brain metastases is permeable. This "leakiness" allows large molecules like the ADC trastuzumab deruxtecan (TDXD) to enter and deliver its payload, providing a mechanism for its high CNS efficacy.